SG10202109691UA - Anti-pacap antibodies and uses thereof - Google Patents

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2869—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
- C07K16/4208—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
- C07K16/4241—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6854—Immunoglobulins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/575—Hormones
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Medicinal Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Immunology (AREA)
Biomedical Technology (AREA)
Genetics & Genomics (AREA)
Molecular Biology (AREA)
Biochemistry (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biophysics (AREA)
Zoology (AREA)
Neurology (AREA)
Endocrinology (AREA)
Biotechnology (AREA)
Neurosurgery (AREA)
Hematology (AREA)
Physical Education & Sports Medicine (AREA)
Wood Science & Technology (AREA)
Gastroenterology & Hepatology (AREA)
Pain & Pain Management (AREA)
Urology & Nephrology (AREA)
Microbiology (AREA)
Diabetes (AREA)
Pulmonology (AREA)
Virology (AREA)
General Engineering & Computer Science (AREA)
Cardiology (AREA)
Cell Biology (AREA)

SG10202109691U2016-04-152017-04-14Anti-pacap antibodies and uses thereofSG10202109691UA (en)

Applications Claiming Priority (6)

Application Number	Priority Date	Filing Date
US201662323495P	2016-04-15	2016-04-15
US201662322939P	2016-04-15	2016-04-15
US201662323573P	2016-04-15	2016-04-15
US201662322957P	2016-04-15	2016-04-15
US201662366902P	2016-07-26	2016-07-26
US201662408347P	2016-10-14	2016-10-14

Publications (1)

Publication Number	Publication Date
SG10202109691UAtrue SG10202109691UA (en)	2021-10-28

Family

ID=60039434

Family Applications (4)

Application Number	Title	Priority Date	Filing Date
SG10202109691USG10202109691UA (en)	2016-04-15	2017-04-14	Anti-pacap antibodies and uses thereof
SG11201808630WASG11201808630WA (en)	2016-04-15	2017-04-14	Humanized anti-pacap antibodies and uses thereof
SG10202109689QSG10202109689QA (en)	2016-04-15	2017-04-14	Humanized anti-pacap antibodies and uses thereof
SG11201808632YASG11201808632YA (en)	2016-04-15	2017-04-14	Anti-pacap antibodies and uses thereof

Family Applications After (3)

Application Number	Title	Priority Date	Filing Date
SG11201808630WASG11201808630WA (en)	2016-04-15	2017-04-14	Humanized anti-pacap antibodies and uses thereof
SG10202109689QSG10202109689QA (en)	2016-04-15	2017-04-14	Humanized anti-pacap antibodies and uses thereof
SG11201808632YASG11201808632YA (en)	2016-04-15	2017-04-14	Anti-pacap antibodies and uses thereof

Country Status (13)

Country	Link
US (9)	US10202435B2 (en)
EP (2)	EP3426686A4 (en)
JP (2)	JP2019515671A (en)
KR (2)	KR20190005873A (en)
CN (2)	CN109311977B (en)
AU (3)	AU2017250815B2 (en)
CA (2)	CA3020839A1 (en)
IL (2)	IL262092B2 (en)
MX (1)	MX2018012470A (en)
NZ (1)	NZ746720A (en)
SG (4)	SG10202109691UA (en)
TW (2)	TW201738272A (en)
WO (2)	WO2017181031A2 (en)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US11951139B2 (en)	2015-11-30	2024-04-09	Seed Health, Inc.	Method and system for reducing the likelihood of osteoporosis
US11998479B2 (en)	2011-02-04	2024-06-04	Seed Health, Inc.	Method and system for addressing adverse effects on the oral microbiome and restoring gingival health caused by sodium lauryl sulphate exposure
US11951140B2 (en)	2011-02-04	2024-04-09	Seed Health, Inc.	Modulation of an individual's gut microbiome to address osteoporosis and bone disease
US12279989B2 (en)	2011-02-04	2025-04-22	Seed Health, Inc.	Method and system for increasing beneficial bacteria and decreasing pathogenic bacteria in the oral cavity
US12257272B2 (en)	2015-12-24	2025-03-25	Seed Health, Inc.	Method and system for reducing the likelihood of developing depression in an individual
US11844720B2 (en)	2011-02-04	2023-12-19	Seed Health, Inc.	Method and system to reduce the likelihood of dental caries and halitosis
US11839632B2 (en)	2013-12-20	2023-12-12	Seed Health, Inc.	Topical application of CRISPR-modified bacteria to treat acne vulgaris
US11969445B2 (en)	2013-12-20	2024-04-30	Seed Health, Inc.	Probiotic composition and method for controlling excess weight, obesity, NAFLD and NASH
US11826388B2 (en)	2013-12-20	2023-11-28	Seed Health, Inc.	Topical application of Lactobacillus crispatus to ameliorate barrier damage and inflammation
US11833177B2 (en)	2013-12-20	2023-12-05	Seed Health, Inc.	Probiotic to enhance an individual's skin microbiome
US11980643B2 (en)	2013-12-20	2024-05-14	Seed Health, Inc.	Method and system to modify an individual's gut-brain axis to provide neurocognitive protection
US12329783B2 (en)	2013-12-20	2025-06-17	Seed Health, Inc.	Method and system to improve the health of a person's skin microbiome
US12005085B2 (en)	2013-12-20	2024-06-11	Seed Health, Inc.	Probiotic method and composition for maintaining a healthy vaginal microbiome
US12246043B2 (en)	2013-12-20	2025-03-11	Seed Health, Inc.	Topical application to treat acne vulgaris
US11998574B2 (en)	2013-12-20	2024-06-04	Seed Health, Inc.	Method and system for modulating an individual's skin microbiome
TWI721976B (en)	2015-04-16	2021-03-21	美商艾爾德生物製藥股份有限公司	Anti-pacap antibodies and uses thereof
CA3020839A1 (en)	2016-04-15	2017-10-19	Alder Biopharmaceuticals, Inc.	Anti-pacap antibodies and uses thereof
EP3732203A4 (en)*	2017-12-28	2021-12-15	Nanjing Legend Biotech Co., Ltd.	Antibodies and variants thereof against pd-l1
JP2022538232A (en)	2019-06-28	2022-09-01	アムジエン・インコーポレーテツド	Anti-CGRP Receptor/Anti-PAC1 Receptor Bispecific Antigen Binding Protein
US20220401439A1 (en)*	2019-12-17	2022-12-22	Biohaven Pharmaceutical Holding Company Ltd.	Intranasal pharmaceutical compositions of cgrp inhibitors
WO2021158962A2 (en)	2020-02-06	2021-08-12	University Of Pittsburgh - Of The Commonwealth System Of Higher Education	T cell receptors targeting defective dna repair proteins
US10822379B1 (en)	2020-03-12	2020-11-03	University of Pittsburgh—of the Commonwealth System of Higher Education	Molecules that bind to SARS-CoV-2
JP7049637B1 (en)*	2020-05-08	2022-04-07	国立大学法人鹿児島大学	Antidepressant / anxiolytic drug using PAC1 receptor antagonist
AU2021385052A1 (en)*	2020-11-19	2023-06-01	Pfizer Ireland Pharmaceuticals	Compositions for improved delivery of cgrp inhibitors
CN113237873B (en)*	2021-03-31	2022-11-29	西南科技大学	Reagent for rapidly detecting content of fentanyl and portable detection equipment
CN113239599A (en)*	2021-06-15	2021-08-10	江苏理工学院	Intelligent tire wear life estimation method and device based on BP neural network
KR20240046192A (en)*	2021-07-29	2024-04-08	세파론 엘엘씨	Compositions and methods for anti-PACAP antibodies
WO2023051786A1 (en)*	2021-09-30	2023-04-06	江苏恒瑞医药股份有限公司	Antigen-binding molecules that specifically bind cgrp and pacap and pharmaceutical use thereof
US20240092880A1 (en)*	2021-10-04	2024-03-21	Mark Hasleton	Treatment of migraine
WO2024171078A1 (en)*	2023-02-14	2024-08-22	H. Lundbeck A/S	Treatment of opiod-induced pain
WO2024261733A1 (en)	2023-06-23	2024-12-26	H. Lundbeck A/S	Combinational treatment

Family Cites Families (113)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4179337A (en)	1973-07-20	1979-12-18	Davis Frank F	Non-immunogenic polypeptides
US4419446A (en)	1980-12-31	1983-12-06	The United States Of America As Represented By The Department Of Health And Human Services	Recombinant DNA process utilizing a papilloma virus DNA as a vector
US4579821A (en)	1981-11-23	1986-04-01	University Patents, Inc.	Control of DNA sequence transcription
US4601978A (en)	1982-11-24	1986-07-22	The Regents Of The University Of California	Mammalian metallothionein promoter system
US4560655A (en)	1982-12-16	1985-12-24	Immunex Corporation	Serum-free cell culture medium and process for making same
US4657866A (en)	1982-12-21	1987-04-14	Sudhir Kumar	Serum-free, synthetic, completely chemically defined tissue culture media
US4816567A (en)	1983-04-08	1989-03-28	Genentech, Inc.	Recombinant immunoglobin preparations
US4767704A (en)	1983-10-07	1988-08-30	Columbia University In The City Of New York	Protein-free culture medium
US4965199A (en)	1984-04-20	1990-10-23	Genentech, Inc.	Preparation of functional human factor VIII in mammalian cells using methotrexate based selection
GB8516415D0 (en)	1985-06-28	1985-07-31	Celltech Ltd	Culture of animal cells
US6548640B1 (en)	1986-03-27	2003-04-15	Btg International Limited	Altered antibodies
US5225539A (en)	1986-03-27	1993-07-06	Medical Research Council	Recombinant altered antibodies and methods of making altered antibodies
US4927762A (en)	1986-04-01	1990-05-22	Cell Enterprises, Inc.	Cell culture medium with antioxidant
GB8725529D0 (en)	1987-10-30	1987-12-02	Delta Biotechnology Ltd	Polypeptides
US4956288A (en)	1988-04-22	1990-09-11	Biogen, Inc.	Method for producing cells containing stably integrated foreign DNA at a high copy number, the cells produced by this method, and the use of these cells to produce the polypeptides coded for by the foreign DNA
EP0435911B1 (en)	1988-09-23	1996-03-13	Cetus Oncology Corporation	Cell culture medium for enhanced cell growth, culture longevity and product expression
WO1990006952A1 (en)	1988-12-22	1990-06-28	Kirin-Amgen, Inc.	Chemically modified granulocyte colony stimulating factor
US5530101A (en)	1988-12-28	1996-06-25	Protein Design Labs, Inc.	Humanized immunoglobulins
US5766883A (en)	1989-04-29	1998-06-16	Delta Biotechnology Limited	Polypeptides
US5198542A (en)	1989-06-20	1993-03-30	Takeda Chemical Industries, Inc.	Dna encoding a pitvitary adenylate cyclase activating protein and use thereof
FR2650598B1 (en)	1989-08-03	1994-06-03	Rhone Poulenc Sante	DERIVATIVES OF ALBUMIN WITH THERAPEUTIC FUNCTION
US5859205A (en)	1989-12-21	1999-01-12	Celltech Limited	Humanised antibodies
US5486472A (en)	1990-03-17	1996-01-23	Takeda Chemical Industries, Ltd.	Monoclonal antibodies to PACAP
CA2090126C (en)	1990-08-02	2002-10-22	John W. Schrader	Methods for the production of proteins with a desired function
US5122469A (en)	1990-10-03	1992-06-16	Genentech, Inc.	Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
FR2669336B1 (en)	1990-11-20	1993-01-22	Adir	NOVEL OXAZOLO PYRIDINES DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM.
WO1994004679A1 (en)	1991-06-14	1994-03-03	Genentech, Inc.	Method for making humanized antibodies
WO1992022653A1 (en)	1991-06-14	1992-12-23	Genentech, Inc.	Method for making humanized antibodies
FR2686899B1 (en)	1992-01-31	1995-09-01	Rhone Poulenc Rorer Sa	NOVEL BIOLOGICALLY ACTIVE POLYPEPTIDES, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM.
US5660827A (en)	1992-03-05	1997-08-26	Board Of Regents, The University Of Texas System	Antibodies that bind to endoglin
WO1994011026A2 (en)	1992-11-13	1994-05-26	Idec Pharmaceuticals Corporation	Therapeutic application of chimeric and radiolabeled antibodies to human b lymphocyte restricted differentiation antigen for treatment of b cell lymphoma
US5604260A (en)	1992-12-11	1997-02-18	Merck Frosst Canada Inc.	5-methanesulfonamido-1-indanones as an inhibitor of cyclooxygenase-2
EP0618291A3 (en)	1993-02-26	1997-12-03	Takeda Chemical Industries, Ltd.	PACAP receptor protein, method for preparing said protein, and use thereof
US5409944A (en)	1993-03-12	1995-04-25	Merck Frosst Canada, Inc.	Alkanesulfonamido-1-indanone derivatives as inhibitors of cyclooxygenase
WO1994021293A1 (en)	1993-03-19	1994-09-29	Duke University	Method of treatment of tumors with an antibody binding to tenascin
US5474995A (en)	1993-06-24	1995-12-12	Merck Frosst Canada, Inc.	Phenyl heterocycles as cox-2 inhibitors
US5436265A (en)	1993-11-12	1995-07-25	Merck Frosst Canada, Inc.	1-aroyl-3-indolyl alkanoic acids and derivatives thereof useful as anti-inflammatory agents
US5643575A (en)	1993-10-27	1997-07-01	Enzon, Inc.	Non-antigenic branched polymer conjugates
US6399316B1 (en)	1994-02-25	2002-06-04	Takeda Chemical Industries, Ltd.	PACAP receptor protein, method for preparing said protein, and use thereof
US5475995A (en)	1994-05-16	1995-12-19	Livingston; George G.	Truck spare tire locking rod
US5616601A (en)	1994-07-28	1997-04-01	Gd Searle & Co	1,2-aryl and heteroaryl substituted imidazolyl compounds for the treatment of inflammation
WO1996004925A1 (en)	1994-08-12	1996-02-22	Immunomedics, Inc.	Immunoconjugates and humanized antibodies specific for b-cell lymphoma and leukemia cells
US5521213A (en)	1994-08-29	1996-05-28	Merck Frosst Canada, Inc.	Diaryl bicyclic heterocycles as inhibitors of cyclooxygenase-2
US5593994A (en)	1994-09-29	1997-01-14	The Dupont Merck Pharmaceutical Company	Prostaglandin synthase inhibitors
US5552422A (en)	1995-01-11	1996-09-03	Merck Frosst Canada, Inc.	Aryl substituted 5,5 fused aromatic nitrogen compounds as anti-inflammatory agents
US5510368A (en)	1995-05-22	1996-04-23	Merck Frosst Canada, Inc.	N-benzyl-3-indoleacetic acids as antiinflammatory drugs
US5639780A (en)	1995-05-22	1997-06-17	Merck Frosst Canada, Inc.	N-benzyl indol-3-yl butanoic acid derivatives as cyclooxygenase inhibitors
US5604253A (en)	1995-05-22	1997-02-18	Merck Frosst Canada, Inc.	N-benzylindol-3-yl propanoic acid derivatives as cyclooxygenase inhibitors
EP0835264A4 (en)	1995-06-06	1998-12-30	Human Genome Sciences Inc	Human g-protein receptor hcegh45
WO1998024900A1 (en)	1996-12-02	1998-06-11	Human Genome Sciences, Inc.	Human g-protein receptor hcegh45, a pacap-like (g-protein pituitary adenylate cyclase activating polypeptide-like) receptor
WO1999051762A1 (en)*	1998-04-03	1999-10-14	Millennium Pharmaceuticals, Inc.	Methods and compositions for the diagnosis and treatment of neuropsychiatric disorders
US20020155533A1 (en)	1998-11-30	2002-10-24	Takeda Chemical	PACAP receptor protein, method for preparing said protein, and use thereof
ES2307534T3 (en)	1999-09-28	2008-12-01	Bayer Corporation	RECEIVER AGONISTS 3 (R3) OF THE ACTIVATOR PEPTIDE OF THE HYPOPHYSIARY CYCLASS ADENYLATE (PACAP) AND ITS PHARMACOLOGICAL USE METHODS.
US20020182729A1 (en)	2001-01-11	2002-12-05	Dicicco-Bloom Emanuel	Pituitary adenylate cyclase-activating polypeptide (PACAP) is an anti-mitogenic signal for selected neuronal precursors in vivo
PL403488A1 (en)	2001-05-24	2013-07-08	Zymogenetics, Inc.	Use of a fusion protein TACI-immunoglobulin fusion protein, a nucleic acid molecule encoding a fusion protein, the pharmaceutical composition and a method for producing the fusion protein TACI-immunoglobulin
CA2481238A1 (en)	2002-03-26	2003-10-09	Massachusetts Institute Of Technology	Targets, methods, and reagents for diagnosis and treatment of schizophrenia
EP1507551A2 (en)	2002-05-03	2005-02-23	Neuronova AB	The functional role and potential therapeutic use of pacap, vip and maxadilan in relation to adult neural stem or progenitor cells
AR040548A1 (en)	2002-07-12	2005-04-13	Bayer Pharmaceuticals Corp	RECEIVER AGONISTS (VPAC2) OF THE ACTIVATING PEPTIDE OF THE HYPOFISARY CYCLASS ADENYLATE (PACAP) AND ITS PHARMACOLOGICAL USE METHODS
GB0216648D0 (en)	2002-07-18	2002-08-28	Lonza Biologics Plc	Method of expressing recombinant protein in CHO cells
EP1583550A2 (en)	2003-01-16	2005-10-12	D. Collen Research Foundation vzw	Inhibition of pacap signalling for the prevention and treatment of thrombocytopenia
US8268582B2 (en)	2003-10-22	2012-09-18	Keck Graduate Institute	Methods of synthesizing heteromultimeric polypeptides in yeast using a haploid mating strategy
US20080070239A1 (en)*	2003-10-29	2008-03-20	University Of Rochester	Detection of neureopeptides associated with pelvic pain disorders and uses thereof
US20050129687A1 (en)	2003-11-03	2005-06-16	University Of Vermont And State Agricultural College	Use of inhibitors of PACAP receptor activity for treatment of overactive bladder and pelvic floor pain syndrome
JP2007519739A (en)	2004-01-27	2007-07-19	バイエル・フアーマシユーチカルズ・コーポレーシヨン	Pituitary cell adenylate cyclase activating peptide (PACAP) receptor (VCAP2) agonists and methods for their pharmaceutical use
US20070202099A1 (en)	2004-03-30	2007-08-30	Hiroshi Inooka	Antibody Drug
KR101150242B1 (en)	2004-10-27	2012-06-13	유니버시티 오브 덴버	Adrenocorticotropic hormone analogs and related methods
US20100068208A1 (en)	2005-04-28	2010-03-18	Kazuhiro Ogi	Degranulation inhibitor
MX2007014673A (en)	2005-05-24	2008-04-08	Avestha Gengraine Tech Pvt Ltd	A method for the production of a monoclonal antibody to cd20 for the treatment of b-cell lymphoma.
WO2007025286A2 (en)	2005-08-26	2007-03-01	The Board Of Trustees Of The Leland Stanford Junior University	Therapy procedure for drug delivery for trigeminal pain
SI2380592T1 (en)	2005-11-14	2018-06-29	Teva Pharmaceuticals International Gmbh	Antagonist antibody directed against calcitonin gene-related peptide
CN101600793B (en)	2006-05-19	2013-06-26	奥尔德生物制药公司	Culture method for obtaining a clonal population of antigen-specific B cells
US20100112601A1 (en)	2006-08-08	2010-05-06	Kyoto University	Novel monoclonal antibody and use of the same
EP2094731A2 (en)	2006-11-10	2009-09-02	UCB Pharma S.A.	Anti human sclerostin antibodies
WO2008131431A2 (en)*	2007-04-23	2008-10-30	St. Louis University	Modulation of blood brain barrier protein expression
HUE043782T2 (en)	2007-05-21	2019-09-30	Alderbio Holdings Llc	Antibodies to il-6 and use thereof
KR20160005134A (en)	2007-05-21	2016-01-13	앨더바이오 홀딩스 엘엘씨	Novel rabbit antibody humanization methods and humanized rabbit antibodies
TW201531484A (en)	2007-05-21	2015-08-16	Alder Biopharmaceuticals Inc	Antibodies to TNF alpha and use thereof
EP2009026A1 (en)	2007-06-29	2008-12-31	ThromboGenics N.V.	Anti-VPAC1 antibodies and their uses
US20100104530A1 (en)*	2007-06-26	2010-04-29	Kathleen Freson	Anti-vpac1 antibodies and their uses
EP2586788B1 (en)	2007-07-09	2017-11-29	Genentech, Inc.	Prevention of disulfide bond reduction during recombinant production of polypeptides
WO2009033489A2 (en)	2007-09-11	2009-03-19	Glostrup Hospital	Selective pacl inhibitors for use in the treatment of migraine and headaches
BRPI0818165B8 (en)	2007-10-12	2021-05-25	Hoffmann La Roche	method of recombinant production of a heterologous immunoglobulin in cho cells that is secreted into the culture medium
KR102157097B1 (en)*	2008-06-25	2020-09-18	노바르티스 아게	Stable and soluble antibodies inhibiting vegf
AU2009270181B2 (en)	2008-07-10	2014-05-29	Toray Industries, Inc.	Pharmaceutical composition for treatment and prevention of cancer
WO2010007175A2 (en)	2008-07-18	2010-01-21	Galderma Research & Development	Pacap signaling pathway modulators for treating inflammatory skin diseases with a neurogenic component, and more particularly rosacea and composition containing them
ES2439966T3 (en)*	2008-11-12	2014-01-27	F. Hoffmann-La Roche Ag	PACAP as a marker for cancer
CN102282256B (en)	2008-12-05	2014-09-17	凯奥目生物科学株式会社	Method for producing antibody directed against protein expressed on cell surface
JO3382B1 (en)	2008-12-23	2019-03-13	Amgen Inc	Human cgrp receptor binding antibodies
US8609097B2 (en)	2009-06-10	2013-12-17	Hoffmann-La Roche Inc.	Use of an anti-Tau pS422 antibody for the treatment of brain diseases
EP3165236B1 (en)	2009-08-28	2022-03-16	Teva Pharmaceuticals International GmbH	Methods for treating visceral pain by administering antagonist antibodies directed against calcitonin gene-related peptide
JP5444088B2 (en)	2010-03-31	2014-03-19	川崎重工業株式会社	Valve plate and axial piston type hydraulic pump / motor equipped with the same
JP5728574B2 (en)	2010-07-21	2015-06-03	アイメックＩｍｅｃ	Method for determining active dopant profile
US11214610B2 (en)	2010-12-01	2022-01-04	H. Lundbeck A/S	High-purity production of multi-subunit proteins such as antibodies in transformed microbes such as Pichia pastoris
US9783602B2 (en)*	2010-12-01	2017-10-10	Alderbio Holdings Llc	Anti-NGF compositions and use thereof
US9939449B2 (en)*	2011-02-01	2018-04-10	The University Of Vermont And State Agricultural College	Diagnostic and therapeutic methods and products related to anxiety disorders
TWI705825B (en)	2011-05-20	2020-10-01	美商艾爾德生物控股有限責任公司	Use of anti-cgrp or anti-cgrp-r antibodies or antibody fragments to treat or prevent chronic and acute forms of diarrhea
PL2710039T3 (en)	2011-05-20	2019-07-31	Alderbio Holdings Llc	Anti-cgrp compositions and use thereof
KR101965461B1 (en)	2011-05-20	2019-04-04	앨더바이오 홀딩스 엘엘씨	Use of anti-cgrp antibodies and antibody fragments to prevent or inhibit photophobia or light aversion in subjects in need thereof, especially migraine sufferers
US8524664B2 (en)	2011-06-02	2013-09-03	Colorado Seminary, Which owns and Operates The Univeristy of Denver	Methods of treating overproduction of cortisol using ACTH antagonist peptides
WO2012170430A1 (en)	2011-06-06	2012-12-13	Cardero Therapeutics, Inc.	Methods and compositions for treatment of mitochondrial toxicity
US10112987B2 (en)	2012-01-09	2018-10-30	Icb International, Inc.	Blood-brain barrier permeable peptide compositions comprising a vab domain of a camelid single domain heavy chain antibody against an amyloid-beta peptide
US9255154B2 (en)*	2012-05-08	2016-02-09	Alderbio Holdings, Llc	Anti-PCSK9 antibodies and use thereof
WO2014146074A2 (en)	2013-03-15	2014-09-18	Alder Biopharmaceuticals, Inc.	Protocol for identifying and isolating antigen-specific b cells and producing antibodies to desired antigens
WO2014145744A1 (en)	2013-03-15	2014-09-18	Alder Biopharmaceuticals, Inc.	Antibody purification and purity monitoring
AU2014228924B2 (en)*	2013-03-15	2019-04-18	Amgen Inc.	Human PAC1 antibodies
UA118028C2 (en)	2013-04-03	2018-11-12	Рош Глікарт Аг	Bispecific antibodies specific for fap and dr5, antibodies specific for dr5 and methods of use
EP3060579A1 (en)*	2013-10-25	2016-08-31	Numab AG	Bispecific constructs and their use in the treatment of various diseases
WO2015100353A1 (en)*	2013-12-27	2015-07-02	Dignity Health	Diagnosing and treating alzheimer's disease
US9688754B2 (en)	2014-02-20	2017-06-27	Alder Biopharmaceuticals, Inc.	Anti-ACTH antibodies and use thereof
TWI721976B (en)	2015-04-16	2021-03-21	美商艾爾德生物製藥股份有限公司	Anti-pacap antibodies and uses thereof
EP3390447A1 (en)*	2015-12-15	2018-10-24	Amgen Inc.	Pacap antibodies and uses thereof
CA3020839A1 (en)*	2016-04-15	2017-10-19	Alder Biopharmaceuticals, Inc.	Anti-pacap antibodies and uses thereof
AR113022A1 (en)*	2017-09-29	2020-01-15	Lilly Co Eli	ANTI-PACAP ANTIBODY

2017
- 2017-04-14CACA3020839Apatent/CA3020839A1/ennot_activeAbandoned
- 2017-04-14CNCN201780036728.1Apatent/CN109311977B/enactiveActive
- 2017-04-14WOPCT/US2017/027660patent/WO2017181031A2/enactiveApplication Filing
- 2017-04-14TWTW106112586Apatent/TW201738272A/enunknown
- 2017-04-14CNCN201780036724.3Apatent/CN109451728A/enactivePending
- 2017-04-14KRKR1020187032682Apatent/KR20190005873A/ennot_activeWithdrawn
- 2017-04-14AUAU2017250815Apatent/AU2017250815B2/enactiveActive
- 2017-04-14WOPCT/US2017/027669patent/WO2017181039A1/enactiveApplication Filing
- 2017-04-14SGSG10202109691Upatent/SG10202109691UA/enunknown
- 2017-04-14NZNZ746720Apatent/NZ746720A/enunknown
- 2017-04-14AUAU2017250807Apatent/AU2017250807A1/ennot_activeAbandoned
- 2017-04-14JPJP2018554092Apatent/JP2019515671A/ennot_activeCeased
- 2017-04-14EPEP17783258.1Apatent/EP3426686A4/enactivePending
- 2017-04-14JPJP2018554033Apatent/JP7116685B2/enactiveActive
- 2017-04-14USUS15/487,607patent/US10202435B2/enactiveActive
- 2017-04-14EPEP17783252.4Apatent/EP3426288A4/ennot_activeWithdrawn
- 2017-04-14KRKR1020187032683Apatent/KR102444717B1/enactiveActive
- 2017-04-14TWTW106112651Apatent/TWI770020B/enactive
- 2017-04-14SGSG11201808630WApatent/SG11201808630WA/enunknown
- 2017-04-14CACA3020990Apatent/CA3020990A1/enactivePending
- 2017-04-14SGSG10202109689Qpatent/SG10202109689QA/enunknown
- 2017-04-14MXMX2018012470Apatent/MX2018012470A/enunknown
- 2017-04-14USUS15/487,642patent/US10913783B2/enactiveActive
- 2017-04-14SGSG11201808632YApatent/SG11201808632YA/enunknown
2018
- 2018-10-03ILIL262092Apatent/IL262092B2/enunknown
- 2018-10-03ILIL262095Apatent/IL262095A/enunknown
2019
- 2019-02-11USUS16/272,406patent/US11352409B2/enactiveActive
2020
- 2020-02-11USUS16/787,250patent/US10954285B2/enactiveActive
- 2020-02-11USUS16/787,313patent/US10968268B2/enactiveActive
- 2020-02-11USUS16/787,260patent/US10975135B2/enactiveActive
- 2020-12-15USUS17/122,243patent/US11938185B2/enactiveActive
2022
- 2022-04-19USUS17/723,674patent/US20230125604A1/enactivePending
2024
- 2024-01-31AUAU2024200599Apatent/AU2024200599A1/enactivePending
- 2024-02-20USUS18/581,446patent/US20250009876A1/enactivePending

Also Published As

Publication number	Publication date
KR20190005874A (en)	2019-01-16
US10975135B2 (en)	2021-04-13
WO2017181031A3 (en)	2017-11-09
SG10202109689QA (en)	2021-10-28
US20170298127A1 (en)	2017-10-19
US10954285B2 (en)	2021-03-23
EP3426686A1 (en)	2019-01-16
TW201738272A (en)	2017-11-01
WO2017181031A2 (en)	2017-10-19
KR20190005873A (en)	2019-01-16
US11352409B2 (en)	2022-06-07
US20200181229A1 (en)	2020-06-11
TW201738273A (en)	2017-11-01
KR102444717B1 (en)	2022-09-16
US10913783B2 (en)	2021-02-09
JP2019513398A (en)	2019-05-30
US10202435B2 (en)	2019-02-12
AU2017250815A1 (en)	2018-10-25
MX2018012470A (en)	2019-07-01
CA3020839A1 (en)	2017-10-19
IL262095A (en)	2018-11-29
CN109451728A (en)	2019-03-08
AU2017250807A1 (en)	2018-10-25
IL262092B (en)	2022-10-01
US20200165316A1 (en)	2020-05-28
US20170298115A1 (en)	2017-10-19
US20200181230A1 (en)	2020-06-11
CN109311977A (en)	2019-02-05
SG11201808632YA (en)	2018-10-30
NZ746720A (en)	2025-05-02
WO2017181039A1 (en)	2017-10-19
US20190233498A1 (en)	2019-08-01
SG11201808630WA (en)	2018-10-30
US20210179688A1 (en)	2021-06-17
IL262092B2 (en)	2023-02-01
AU2017250815B2 (en)	2023-11-23
AU2024200599A1 (en)	2024-02-22
JP7116685B2 (en)	2022-08-10
US10968268B2 (en)	2021-04-06
EP3426288A2 (en)	2019-01-16
US11938185B2 (en)	2024-03-26
EP3426288A4 (en)	2019-10-30
IL262092A (en)	2018-11-29
US20230125604A1 (en)	2023-04-27
JP2019515671A (en)	2019-06-13
TWI770020B (en)	2022-07-11
US20250009876A1 (en)	2025-01-09
CA3020990A1 (en)	2017-10-19
CN109311977B (en)	2022-06-14
EP3426686A4 (en)	2019-11-06

Publication	Publication Date	Title
IL290842A (en)	2022-04-01	Anti-cd73 antibodies and uses thereof
IL283321A (en)	2021-07-29	Anti-muc16 antibodies and uses thereof
IL280648A (en)	2021-03-25	Anti-galectin-9 antibodies and uses thereof
IL266738A (en)	2019-07-31	Novel antibodies and uses thereof
IL271477A (en)	2020-01-30	Anti-cd166 antibodies and uses thereof
IL264970A (en)	2019-04-30	Anti-tim-3 antibodies and use thereof
IL268734A (en)	2019-10-31	Anti-lag-3 antibodies and uses thereof
IL268700A (en)	2019-10-31	Anti-phf-tau antibodies and uses thereof
IL258284A (en)	2018-05-31	Anti-lag3 antibodies and uses thereof
IL257263A (en)	2018-03-29	Anti-angptl8 antibodies and uses thereof
SG11201808632YA (en)	2018-10-30	Anti-pacap antibodies and uses thereof
ZA201800536B (en)	2019-07-31	Il-8-binding antibodies and uses thereof
EP3541840C0 (en)	2023-12-27	Anti-hla-g antibodies and use thereof
IL254955A0 (en)	2017-12-31	Anti-pacap antibodies and uses thereof
ZA201901935B (en)	2020-11-25	Anti-il-33 antibodies and uses thereof
IL269134A (en)	2019-11-28	Anti-par2 antibodies and uses thereof
IL273157A (en)	2020-04-30	Axl-specific antibodies and uses thereof
IL272476A (en)	2020-03-31	Anti-apelin antibodies and uses thereof
PT3292154T (en)	2022-01-26	Anti-human-her3 antibodies and uses thereof
GB201503387D0 (en)	2015-04-15	Anti-carbapenem antibodies and uses thereof
IL266049A (en)	2019-06-30	Anti-o1 antibodies and uses thereof
IL264417A (en)	2019-02-28	Anti-o2 antibodies and uses thereof
IL266082A (en)	2019-06-30	Anti-chikv antibodies and uses thereof
GB201712032D0 (en)	2017-09-06	Antibodies and uses thereof

Movatterモバイル変換

SG10202109691UA - Anti-pacap antibodies and uses thereof - Google Patents

Info

Links

Classifications

Landscapes

Applications Claiming Priority (6)

Publications (1)

Family

ID=60039434

Family Applications (4)

Family Applications After (3)

Country Status (13)

Families Citing this family (31)

Family Cites Families (113)

Also Published As

Similar Documents